• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryCurrent TOCInstructions for authors
J Neurol Neurosurg Psychiatry. Dec 1990; 53(12): 1051–1055.
PMCID: PMC488313

Vigabatrin: rational treatment for chronic epilepsy.


Vigabatrin is a selective, irreversible suicide inhibitor of GABA transaminase and thus increases brain and CSF GABA. In 33 adult patients with long standing refractory epilepsy on treatment with one or two standard anti-convulsant drugs, the addition of vigabatrin up to 3g daily for eight weeks was associated with a 48.2% reduction in seizure frequency. Twenty patients who had exhibited a 50% or more reduction in frequency of one or more seizure types entered an eight week double-blind placebo controlled phase. Patients on vigabatrin maintained a 54.7% reduction of seizure frequency, whereas those on placebo showed an 18.6% increase in seizure frequency, a highly significant difference between the two groups. In the open phase, seven patients were withdrawn due to unacceptable and reversible adverse events. The commonest side effects were drowsiness, depression and mood instability, and headaches. Vigabatrin is a potentially valuable new treatment for chronic epilepsy, especially partial seizures with or without secondary generalisation.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (923K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Meldrum BS. Gamma-aminobutyric acid and the search for new anticonvulsant drugs. Lancet. 1978 Aug 5;2(8084):304–306. [PubMed]
  • Jung MJ, Lippert B, Metcalf BW, Böhlen P, Schechter PJ. gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977 Nov;29(5):797–802. [PubMed]
  • Schechter PJ, Hanke NF, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology. 1984 Feb;34(2):182–186. [PubMed]
  • Gram L, Lyon BB, Dam M. Gamma-vinyl-GABA: a single-blind trial in patients with epilepsy. Acta Neurol Scand. 1983 Jul;68(1):34–39. [PubMed]
  • Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Napoliello MJ, Sherry KM, Szabo GK. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology. 1987 Feb;37(2):184–189. [PubMed]
  • Rimmer EM, Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet. 1984 Jan 28;1(8370):189–190. [PubMed]
  • Gram L, Klosterskov P, Dam M. gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol. 1985 Mar;17(3):262–266. [PubMed]
  • Dreifuss FE. Report on the International League Against Epilepsy. Epilepsia. 1986 Jan-Feb;27(1):1–2. [PubMed]
  • Tartara A, Manni R, Galimberti CA, Hardenberg J, Orwin J, Perucca E. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. Epilepsia. 1986 Nov-Dec;27(6):717–723. [PubMed]
  • Tassinari CA, Michelucci R, Ambrosetto G, Salvi F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol. 1987 Sep;44(9):907–910. [PubMed]
  • Amery W, Dony J. A clinical trial design avoiding undue placebo treatment. J Clin Pharmacol. 1975 Oct;15(10):674–679. [PubMed]
  • Albus M, von Gellhorn K, Münch U, Naber D, Ackenheil M. A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results. Psychiatry Res. 1986 Sep;19(1):1–7. [PubMed]
  • Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15(2):143–148. [PubMed]
  • Hauw JJ, Trottier S, Boutry JM, Sun P, Sazdovitch V, Duyckaerts C. The neuropathology of vigabatrin. Br J Clin Pract Suppl. 1988 Mar;61:10–13. [PubMed]
  • Pedersen B, Højgaard K, Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res. 1987 Jan;1(1):74–76. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...